$PURE
PURE BIOSCIENCE, INC. Stock $pure

$pure Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000149315222029844 Filed on October 28, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$467.0K	$412.0K	$1.813M
YoY Change	-6.79%	-52.04%	-53.83%
Cost Of Revenue	$214.0K	$600.0K	$853.0K
YoY Change	24.42%	-0.33%	-53.94%
Gross Profit	$257.0K	-$188.0K	$1.000M
YoY Change	-21.88%	-173.15%	-51.81%
Gross Profit Margin	55.03%	-45.63%	55.16%
Selling, General & Admin	$1.165M	$979.0K	$4.106M
YoY Change	10.22%	7.46%	3.95%
% of Gross Profit	453.31%		410.6%
Research & Development	$78.00K	$64.00K	$319.0K
YoY Change	16.42%	-13.51%	-5.9%
% of Gross Profit	30.35%		31.9%
Depreciation & Amortization	$30.00K	$51.00K	$146.0K
YoY Change	-48.28%	30.77%	-15.12%
% of Gross Profit	11.67%		14.6%
Operating Expenses	$1.243M	$1.043M	$4.724M
YoY Change	10.59%	5.89%	7.71%
Operating Profit	-$986.0K	-$1.231M	-$3.724M
YoY Change	24.03%	69.09%	61.14%
Interest Expense	$2.000K	-$3.000K	$6.000K
YoY Change	-300.0%	200.0%	-250.0%
% of Operating Profit
Other Income/Expense, Net	-$7.000K	$1.000K	$233.0K
YoY Change	600.0%	-125.0%	-5925.0%
Pretax Income	-$993.0K	-$1.233M	-$3.491M
YoY Change	24.75%	68.21%	50.54%
Income Tax			$1.650K
% Of Pretax Income
Net Earnings	-$993.0K	-$1.233M	-$3.491M
YoY Change	24.75%	68.21%	50.54%
Net Earnings / Revenue	-212.63%	-299.27%	-192.55%
Basic Earnings Per Share	-$0.01		-$0.04
Diluted Earnings Per Share	-$8.917K	-$13.39K	-$39.30K
COMMON SHARES
Basic Shares Outstanding	111.4M shares		88.84M shares
Diluted Shares Outstanding	111.4M shares		88.84M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.452M	$3.391M	$3.391M
YoY Change	39.32%	41.88%	41.88%
Cash & Equivalents	$2.452M	$3.391M	$3.391M
Short-Term Investments
Other Short-Term Assets	$129.0K	$93.00K	$93.00K
YoY Change	-9.79%	-13.08%	-13.08%
Inventory	$239.0K	$179.0K	$179.0K
Prepaid Expenses	$54.00K	$18.00K
Receivables	$252.0K	$201.0K	$201.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.072M	$3.864M	$3.864M
YoY Change	25.23%	20.86%	20.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$627.0K	$620.0K	$620.0K
YoY Change	-18.47%	-16.22%	-16.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$627.0K	$620.0K	$620.0K
YoY Change	-43.1%	-43.94%	-43.94%
TOTAL ASSETS
Total Short-Term Assets	$3.072M	$3.864M	$3.864M
Total Long-Term Assets	$627.0K	$620.0K	$620.0K
Total Assets	$3.699M	$4.484M	$4.484M
YoY Change	4.05%	4.21%	4.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$561.0K	$488.0K	$488.0K
YoY Change	20.65%	-17.71%	-17.71%
Accrued Expenses	$138.0K	$87.00K	$87.00K
YoY Change	11.29%	-36.96%	-36.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$699.0K	$575.0K	$575.0K
YoY Change	-15.58%	-40.72%	-40.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$699.0K	$575.0K	$575.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$699.0K	$575.0K	$575.0K
YoY Change	-15.58%	-40.72%	-40.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$130.0M	-$129.3M
YoY Change		2.78%
Common Stock	$1.114M	$1.114M
YoY Change		27.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.000M	$3.909M	$3.909M
YoY Change
Total Liabilities & Shareholders Equity	$3.699M	$4.484M	$4.484M
YoY Change	4.05%	4.21%	4.21%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$993.0K	-$1.233M	-$3.491M
YoY Change	24.75%	68.21%	50.54%
Depreciation, Depletion And Amortization	$30.00K	$51.00K	$146.0K
YoY Change	-48.28%	30.77%	-15.12%
Cash From Operating Activities	-$902.0K	-$603.0K	-$2.418M
YoY Change	56.6%	46.36%	107.2%
INVESTING ACTIVITIES
Capital Expenditures	$37.00K	-$17.00K	$81.00K
YoY Change	-168.52%	0.0%	-115.55%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$37.00K	-$17.00K	-$81.00K
YoY Change	-31.48%	0.0%	-84.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.500M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.500M	$3.500M
YoY Change			1364.44%
NET CHANGE
Cash From Operating Activities	-$902.0K	-603.0K	-$2.418M
Cash From Investing Activities	-$37.00K	-17.00K	-$81.00K
Cash From Financing Activities		3.500M	$3.500M
Net Change In Cash	-$939.0K	2.880M	$1.001M
YoY Change	49.05%	-771.33%	-169.08%
FREE CASH FLOW
Cash From Operating Activities	-$902.0K	-$603.0K	-$2.418M
Capital Expenditures	$37.00K	-$17.00K	$81.00K
Free Cash Flow	-$939.0K	-$586.0K	-$2.499M
YoY Change	79.89%	48.35%	286.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001006028
CY2022	dei	Entity File Number EntityFileNumber	001-14468
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	PURE	Stock Issued During Period Issuance Of Common Stock For Vested Restricted Stock Units StockIssuedDuringPeriodIssuanceOfCommonStockForVestedRestrictedStockUnits		usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf		usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	PURE	Net Proceeds From Payroll Protection Program Loan NetProceedsFromPayrollProtectionProgramLoan		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Registrant Name EntityRegistrantName	PURE Bioscience, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0530289
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	9669 Hermosa Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rancho Cucamonga
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91730
CY2022	dei	City Area Code CityAreaCode	(619)
CY2022	dei	Local Phone Number LocalPhoneNumber	596-8600
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	14400000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111356473	shares
CY2022	dei	Auditor Firm AuditorFirmId	572
CY2022	dei	Auditor Name AuditorName	Weinberg and Company, P.A
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3391000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2390000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201000	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	368000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	179000	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	332000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	75000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	75000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18000	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	3864000	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	3197000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	620000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	740000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	366000	usd
CY2022Q3	us-gaap	Assets Assets	4484000	usd
CY2021Q3	us-gaap	Assets Assets	4303000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	488000	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	593000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87000	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	138000	usd
CY2021Q3	us-gaap	Loans Payable Current LoansPayableCurrent	239000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	575000	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	970000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	575000	usd
CY2021Q3	us-gaap	Liabilities Liabilities	970000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111356473	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111356473	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87223141	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87223141	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1114000	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	873000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	132079000	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	128253000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129284000	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125793000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3909000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	3333000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4484000	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4303000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1853000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3927000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	853000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1852000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1000000	usd
CY2021	us-gaap	Gross Profit GrossProfit	2075000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4106000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4047000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	319000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	339000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	299000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4724000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4386000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3724000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2311000	usd
CY2022	us-gaap	Interest Expense InterestExpense	6000	usd
CY2021	us-gaap	Interest Expense InterestExpense	4000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	239000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	233000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3491000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	88835424	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	87174312	shares
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	4811000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	758000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	83000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	3333000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3500000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	465000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	102000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3491000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3909000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3491000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2319000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	567000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	841000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	55000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	213000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	172000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	75000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	150000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	299000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	239000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-167000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-721000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-78000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-65000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-14000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	16000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-156000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-781000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2418000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1167000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	521000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-521000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	usd
CY2021	PURE	Net Proceeds From Payroll Protection Program Loan NetProceedsFromPayrollProtectionProgramLoan	239000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3500000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	239000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1001000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1449000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2465000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3914000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3466000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2465000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3391000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2390000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	75000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	75000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3466000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2465000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
CY2022Q3	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	129000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3491000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1853000	usd
CY2022	PURE	Net Cash Provided By Used In Operating And Investing Activities NetCashProvidedByUsedInOperatingAndInvestingActivities	2499000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3391000	usd
CY2022	us-gaap	Revenues Revenues	1813000	usd
CY2021	us-gaap	Revenues Revenues	3698000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zaggsXSFan58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_zbC4Q1CbNrHk">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	17000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	160000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	75000	usd
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	75000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	150000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	315000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	299000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	19000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zzbY8m6CDKD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86D_z0Ar0mCND0a">Concentrations</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross sales</i>. For the year ended July 31, 2022, three individual customers accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zHkcj1wqphrc" title="Concentration risk percentage">14</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_ztzNvNugOy01" title="Concentration risk percentage">13</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_zDFCejkNSOr5" title="Concentration risk percentage">10</span>% of our net product sales. No other individual customer accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerMember_zkuGBNFlqqRk">10</span>% or more of our net product sales. The geographic breakdown of net product sales was as follows: 100% U.S. For the year ended July 31, 2021, one individual customer accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zxyqKDGdSEZ5">11</span>% of our net product sales. No other individual customer accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerMember_zBSjMYRAAGzd">10</span>% or more of our net product sales. The geographic breakdown of net product sales was as follows: 100% U.S.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts receivable. </i>As of July 31, 2022, we had accounts receivable from one customer that comprised <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zk1a9VEwB9k2">15</span>% of total accounts receivable and two customers that comprised <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z77nufF43dK">13</span>% of total accounts receivable, respectively. As of July 31, 2021, we had accounts receivable from three customers that comprised <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_za87sLGFb2g2">17</span>%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zwl6zkig5hV4">15</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zczXPlTdmaH8">10</span>% of total accounts receivable, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchases. </i>For the fiscal year ended July 31, 2022, one vendor accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_ztUl77YuPmpk">19</span>% of our purchases. For the fiscal year ended July 31, 2021, one vendor accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zH92v3hiNMHc">36</span>% of our purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts payable.</i> As of July 31, 2022, one vendor accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z910cqUtaQL7">25</span>% of the total trade accounts payable. As of July 31, 2021, one vendor accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200801__20210731__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_zZ2LOn8ITUSj" title="Concentration risk percentage">50</span>% of the total trade accounts payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7291625	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10984390	shares
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segments
CY2022Q3	us-gaap	Inventory Net InventoryNet	179000	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	332000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	225000	usd
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	150000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1660000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1579000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1040000	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	839000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	620000	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	740000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	55000	usd
CY2022	us-gaap	Depreciation Depreciation	146000	usd
CY2021	us-gaap	Depreciation Depreciation	97000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	327765	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	327765	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	327765	shares
CY2022	PURE	Schedule Of Stock Option Outstanding And Exercisable ScheduleOfStockOptionOutstandingAndExercisable	<p id="xdx_89A_ecustom--ScheduleOfStockOptionOutstandingAndExercisable_zXX2NNaYsuxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Stock Option Outstanding and Exercisable </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Exercisable</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life <br/> (in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1phTQVgmOZk" title="Range of Exercise Prices Lower">0.22</span> to $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z52Jt9sU4pub" title="Range of Exercise Prices Upper">0.50</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z3Nq0eJicsGi" style="width: 11%; text-align: right" title="Number of shares outstanding, outstanding">3,080,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zotbBK4U6u2j" title="Weighted Average Remaining Contractual Life, Outstanding">8.17</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zTrMmlx9Tu6k" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding">0.39</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zWGNsBZFe97" style="width: 11%; text-align: right" title="Number of shares outstanding, Exercisable">2,673,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6Sc5L9UjXpc" title="Weighted Average Remaining Contractual Life, Exercisable">8.04</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zQy1GoxMWW98" title="Weighted Average Exercise Price, Exercisable">0.39</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z1prKFN4IlN8" title="Range of Exercise Prices Lower">0.51</span> to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zBkiUS57AMM6" title="Range of Exercise Prices Upper">1.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zhY9r2AOe4X3" style="text-align: right" title="Number of shares outstanding, outstanding">2,443,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zRNw9R3q0Zwd" title="Weighted Average Remaining Contractual Life, Outstanding">4.62</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zh6o7rBcMQWb" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">0.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zp7zfQbcsWck" style="text-align: right" title="Number of shares outstanding, Exercisable">2,443,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrVcwPJJz8ze" title="Weighted Average Remaining Contractual Life, Exercisable">4.62</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbB1e8sZYYL" style="text-align: right" title="Weighted Average Exercise Price, Exercisable">0.77</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zdyefPQFrRVa" title="Range of Exercise Prices Lower">1.01</span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1O5qAgDelvl" title="Range of Exercise Prices Upper">1.40</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zprl4Xsw7JX9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares outstanding, outstanding">555,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zufuFT5n5PT9" title="Weighted Average Remaining Contractual Life, Outstanding">5.37</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zTd8u1uDszP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding">1.20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z65GKCPSh0Oh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares outstanding, Exercisable">505,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210801__20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmmdwRhjPyWg" title="Weighted Average Remaining Contractual Life, Exercisable">5.11</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z2AzL5IT2N9f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220731_zNkEUMHS1cWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares outstanding, outstanding">6,079,125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210801__20220731_zRN472auYVkl" title="Weighted Average Remaining Contractual Life, Outstanding">6.49</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220731_zUu8b2AJRPSi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding">0.62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220731_z7epaQLewsF" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares outstanding, Exercisable">5,621,625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210801__20220731_z4yesDfziOQf" title="Weighted Average Remaining Contractual Life, Exercisable">6.29</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220731_zxY1HDRc4MG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6079125	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M26D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.62
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5621625	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M14D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.62
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8835	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8776	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0117	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0092	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M2D
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1650	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1650	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	107300000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	63300000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27360000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26850000	usd
CY2022Q3	PURE	Deferred Tax Assets Stock Options And Warrants DeferredTaxAssetsStockOptionsAndWarrants	2160000	usd
CY2021Q3	PURE	Deferred Tax Assets Stock Options And Warrants DeferredTaxAssetsStockOptionsAndWarrants	2110000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-10000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-120000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29510000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28840000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29510000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28840000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.28	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.28	pure
CY2022Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2021Q3	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd

Files In Submission

Name	View Source	Status
form10-k_htm.xml	Edgar Link	completed
0001493152-22-029844-index-headers.html	Edgar Link	pending
0001493152-22-029844-index.html	Edgar Link	pending
0001493152-22-029844.txt	Edgar Link	pending
0001493152-22-029844-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pure-20220731.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pure-20220731_cal.xml	Edgar Link	unprocessable
pure-20220731_def.xml	Edgar Link	unprocessable
pure-20220731_pre.xml	Edgar Link	unprocessable
pure-20220731_lab.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PURE
PURE BIOSCIENCE, INC. Stock $pure

2022 Q4 Form 10-K Financial Statement

#000149315222029844 Filed on October 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PURE PURE BIOSCIENCE, INC. Stock $pure

2022 Q4 Form 10-K Financial Statement

#000149315222029844 Filed on October 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PURE
PURE BIOSCIENCE, INC. Stock $pure